9/12/2013

The NIH will give NovelMed Therapeutics $1.43 million to advance its lead antibody drug candidate for paroxysmal nocturnal hemoglobinuria, a rare blood condition. The initial installment of the grant will be used to compare the drug with eculizumab.

Related Summaries